A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection

Status:
Terminated

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.

Phase 3

Medigen Biotechnology Corporation